Hu Jinbo, Yang Shumin, Wang Yue, Goswami Richa, Peng Chuan, Gao Rufei, Zhou Huang, Zhang Yi, Cheng Qingfeng, Zhen Qianna, Li Qifu
Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical University, No.1 Youyi Street, Yuzhong District, Chongqing, 400016, China.
Hospital of Chongqing University, Chongqing, 400044, China.
Acta Diabetol. 2015 Dec;52(6):1135-41. doi: 10.1007/s00592-015-0801-5. Epub 2015 Sep 1.
Bisphenol A (BPA) is associated with diabetes and cardiovascular diseases. The aim of our study was to evaluate whether serum BPA could predict the progression of chronic kidney disease (CKD) in patients with type 2 diabetes (T2D).
In this prospective study, a total of 121 patients with T2D and estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m(2) were followed up for 6 years. The baseline values of serum BPA were measured. Renal function was measured as eGFR calculated by the Chronic Kidney Disease Epidemiology Collaboration creatinine-cystatin C equation. Development of CKD was defined as eGFR < 60 mL/min/1.73 m(2) at the last follow-up. Regression models were used to analyze the associations of serum BPA with the change in eGFR and the risk of CKD development.
Baseline serum BPA concentration was 0.40 (0.17, 1.40) ng/mL. Duration of T2D, baseline waist circumference, systolic blood pressure, diastolic blood pressure, fasting plasma glucose, and serum BPA level were significantly negatively associated with the annual change and percentage change in eGFR. After adjusting for clinical factors, baseline serum BPA level had a significant negative association with the annual change in eGFR (β = -0.371, P < 0.001) and percentage change in eGFR (β = -0.391, P = <0.001). Multivariate logistic regression analysis showed that patients with high levels of serum BPA exhibited about a sevenfold increased risk of developing CKD compared to patients with low levels of serum BPA [odds ratio (OR) 6.65 (95 % CI 1.47, 30.04), P = 0.014].
Serum BPA may be a predictor of CKD in patients with T2D.
双酚A（BPA）与糖尿病和心血管疾病有关。我们研究的目的是评估血清BPA是否能预测2型糖尿病（T2D）患者慢性肾脏病（CKD）的进展。
在这项前瞻性研究中，共有121例T2D患者且估计肾小球滤过率（eGFR）≥60 mL/min/1.73 m²，随访6年。测量血清BPA的基线值。肾功能通过慢性肾脏病流行病学协作组肌酐-胱抑素C方程计算的eGFR来衡量。CKD的发生定义为最后一次随访时eGFR<60 mL/min/1.73 m²。采用回归模型分析血清BPA与eGFR变化及CKD发生风险之间的关联。
血清BPA基线浓度为0.40（0.17，1.40）ng/mL。T2D病程、基线腰围、收缩压、舒张压、空腹血糖和血清BPA水平与eGFR的年变化和百分比变化显著负相关。调整临床因素后，基线血清BPA水平与eGFR的年变化（β = -0.371，P < 0.001）和eGFR的百分比变化（β = -0.391，P = <0.001）显著负相关。多因素logistic回归分析显示，血清BPA水平高的患者发生CKD的风险比血清BPA水平低的患者增加约7倍[比值比（OR）6.65（95%CI 1.47，30.04），P = 0.014]。
血清BPA可能是T2D患者CKD的一个预测指标。
